Compare
Ovid Therapeutics Inc. vs Whitehawk Therapeutics, Inc. vs Xenon Pharmaceuticals Inc. vs Immunome Inc.
| Latest fiscal year | Ovid Therapeutics Inc. OVID | Whitehawk Therapeutics, Inc. WHWK | Xenon Pharmaceuticals Inc. XENE | Immunome Inc. IMNM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $7.25M | $7.14M | $7.50M | $6.94M |
| Revenue growth (YoY) | n/m | -72.5% | n/a | -23.2% |
| Gross margin | n/a | 89.4% (computed) | n/a | n/a |
| Operating margin | -585.2% | n/m | n/m | n/m |
| Net margin | -240.1% | -288.3% | n/m | n/m |
| Net income | -$17.41M | -$20.60M | -$345.91M | -$212.39M |
| EPS (Diluted) | n/a | -$0.33 | -$4.36 | -$2.43 |
| Operating cash flow | -$38.33M | -$97.43M | -$279.12M | -$190.92M |
| Free cash flow | -$38.33M | -$97.98M | -$279.92M | -$200.60M |
| Cash & equivalents | $13.15M | $37.57M | $199.16M | $653.48M |
| Total assets | $150.93M | $150.83M | $633.16M | $683.19M |
| Total liabilities | $20.27M | $14.52M | $51.40M | $48.84M |
| Shareholders' equity | $130.66M | $136.31M | $581.76M | $634.34M |
| Return on year-end equity | -13.3% | -15.1% | -59.5% | -33.5% |
| Shares outstanding | 130.18M | 47.15M | 80.01M | 113.13M |
Revenue, most recent five fiscal years
| Fiscal year | Ovid Therapeutics Inc. | Whitehawk Therapeutics, Inc. | Xenon Pharmaceuticals Inc. | Immunome Inc. |
|---|---|---|---|---|
| Latest | $7.25M Ended 2025-12-31 | $7.14M Ended 2025-12-31 | $7.50M Ended 2025-12-31 | $6.94M Ended 2025-12-31 |
| 1 year earlier | $566.0K Ended 2024-12-31 | $25.98M Ended 2024-12-31 | $0 Ended 2024-12-31 | $9.04M Ended 2024-12-31 |
| 2 years earlier | $392.0K Ended 2023-12-31 | $24.35M Ended 2023-12-31 | $0 Ended 2023-12-31 | $14.02M Ended 2023-12-31 |
| 3 years earlier | $1.50M Ended 2022-12-31 | $15.22M Ended 2022-12-31 | $9.43M Ended 2022-12-31 | n/a |
| 4 years earlier | $208.38M Ended 2021-12-31 | $14.00M Ended 2021-12-31 | $18.44M Ended 2021-12-31 | n/a |